Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2007-11-13
2007-11-13
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S093700, C424S093710, C424S577000
Reexamination Certificate
active
10314035
ABSTRACT:
Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and methods of using Flt3-ligand in hematopoietic cell transplantation.
REFERENCES:
patent: 4745099 (1988-05-01), Akamatsu et al.
patent: 5013824 (1991-05-01), Abrams et al.
patent: 5057420 (1991-10-01), Massey
patent: 5061620 (1991-10-01), Tsukamoto et al.
patent: 5114710 (1992-05-01), Takaku et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5185438 (1993-02-01), Lemischka
patent: 5192553 (1993-03-01), Boyse et al.
patent: 5199942 (1993-04-01), Gillis
patent: 5270458 (1993-12-01), Lemischka
patent: 5283354 (1994-02-01), Lemischka
patent: 5326558 (1994-07-01), Turner et al.
patent: 5367057 (1994-11-01), Lemischka
patent: 5397706 (1995-03-01), Correa et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5399493 (1995-03-01), Emerson et al.
patent: 5437994 (1995-08-01), Emerson et al.
patent: 5453357 (1995-09-01), Hogan
patent: 5459069 (1995-10-01), Palsson et al.
patent: 5525708 (1996-06-01), Nocka et al.
patent: 5548065 (1996-08-01), Lemischka
patent: 5554512 (1996-09-01), Lyman et al.
patent: 5627025 (1997-05-01), Steinman et al.
patent: 5635388 (1997-06-01), Bennett et al.
patent: 5843423 (1998-12-01), Lyman et al.
patent: 0 627 487 (1994-12-01), None
patent: WO 92/18615 (1992-10-01), None
patent: WO 93/08268 (1993-04-01), None
patent: WO 94/26891 (1994-11-01), None
patent: WO 94/28391 (1994-12-01), None
patent: WO 95/00551 (1995-01-01), None
Anderson, W., “Gene Therapy: The best of times, the worst of times,”Science, 228(5466):627-629, 2000.
Attwood, T., “The babel of bioinformatics,”Science, 290:47-49, 2000.
Bernhard et al., “Generation of immunostimulatory dendritic cells from human CD34+hematopoietic progenitor cells of the bone marrow and peripheral blood,”Cancer Res., 55:1099-1104, 1995.
Birg et al., “Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages,”Blood, 80(10):2584-2593, 1992.
Boon, T., “Toward a genetic analysis of tumor rejection antigens,”Adv. In Can. Res., 58:177-211, 1992.
Broxmeyer et al., “Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells,”Exp. Hematol., 23:1121-1129, 1995.
Broxmeyer et al., “Commentary: A rapid proliferation assay for unknown co-stimulating factors in cord blood plasma possibly involved in enhancement of in vitro expansion and replating capacity of human hematopoietic stem/progenitor cells,”Blood Cells, 20(2-3):492-497, 1994.
Brugger et al., “Ex vivo expansion of enriched peripheral blood CD34+progenitor cells by stem cell factor, interleukin-1β (IL-1β), IL-6, IL-3, Interferon-γ, and erythropoietin,”Blood, 81(10):2579-2584, 1993.
Cadena et al., “Receptor tyrosine kinases,”FASEB, 6:2332-2337, 1992.
Chatterjee et al., “Idiotypic antibody immunotherapy of cancer,”Cancer Immunol., 38:75082, 1994.
Chen et al., “antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model,”Cancer Res., 57:3511-3516, 1997.
Culver et al., “Lymphocytes as cellular vehicles for gene therapy in mouse and man,”Proc. Natl. Acad. Sci. USA, 88:3155-3159, 1991.
Debets, R. and Savelkoul, H., “Cytokine antagonists and their potential therapeutic use,”Immunol. Today, 15(10):455-458, 1994.
de Vries et al., “The effect of the Flt3 ligand on purified murine pluripotent hematopoietic stem cells,”J. Cell. Biochem., Suppl. 18B:177, Abst. #H110, 1994.
de Vries et al., “The role of flt3 ligand in early murine hematopoiesis,”Blood, 84:279a, Abst. #1100, 1994.
Dosil et al., “Mitogenic signalling and substrate specificity of the flk2/flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells,”Mol. And Cell. Biol., 13(10):6572-6585, 1993.
Durand et al., “Long-term generation of colony-forming cells (CFC) from CD34+human umbilical cord blood cells,”Leukemia and Lymphoma, 11:263-273, 1993.
Flanagan et al., “Thekitligand: A cell surface molecule altered in steel mutant fibroblasts,”Cell, 63:185194, 1990.
Hanahan, D., “Transgenic mice as probes into complex systems,”Science, 246:1265-1275, 1989.
Hannum et al., “Ligand for Flt3/Flk2 receptor tyrosine kinase regulates growth of hematopoietic stem cells and is encoded by variant RNAs,”Nature, 368:643-648, 1994.
Juan et al., “Chronic expression of murine flt3 ligand in mice results in increased circulating white blood cell levels and abnormal cellular infiltrates associated with splenic fibrosis,”Blood, 90(1):76-84, 1997.
Lardon et al., “Transforming growth factor-β regulates the cell cycle status of interleukin-3 (IL-3) plus IL-1, stem cell factor, or IL-6 stimulated CD34+human hematopoietic progenitor cells through different cell kinetic mechanisms depending on the applied stimulus,”Exp. Hematol., 22:903-909, 1994.
Lotem, J. and Sachs, L., “Control of in vivo differentiation of myeloid leukemic cells,”Leukemia, 2(12):24S-37S, 1988.
Lyman et al., “Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells,”Cell, 75:1157-1167, 1993.
Lyman et al., “Characterization of the protein encoded by the flt3(flk2) receptor-like tyrosine kinase gene,”Oncogene, 8:815-822, 1993.
Lyman et al., “Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells,”Blood, 83(10):2795-2801, 1994.
Lyman, S. and Jacobsen, S., “c-kitligand and flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities,”Blood, 91(4):1101-1134, 1998.
Lynch et al., “Flt3 ligand induces tumor regression and antitumor immune responses in vivo,”Nat. Med., 3(6):625-631, 1997.
Maraskovsky et al., “Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified,”J. Exp. Med., 184:1953-1962, 1996.
Maroc et al., “Biochemical characterization and analysis of the transforming potential of the Flt3/Flk2 receptor tyrosine kinase,”Oncogene, 8:909-918, 1993.
Matthews et al., “A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations,”Cell, 65:1143-1152, 1991.
McBride, G. “New molecule under study: Flt3 Ligand may mobilize dendritic cells,”J. of Nat Cancer Inst., 89(17):1257, 1997.
Ngo et al., “Computational complexity, protein structure prediction, and the levinthal paradox,”Birkhauser Boston, 14:491-495, 1994.
Palsson et al., “Expansion of human bone marrow progenitor cells in a high cell density continuous perfusion system,”Biothechnol., 11:368-372, 1993.
Papayannopoulou et al., “In vivo effects of Flt3/Flt2 ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor,”Blood, 90(2):620-629, 1997.
Porgador, A. and Gilboa, E., “Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes,”J. Exp. Med., 182:255-260, 1995.
Pulendran et al., “Developmental pathways of dendritic cells in vivo,”J. of Immunol., 159:2222-2231, 1997.
Rosnet et al., “Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene,”Genomics, 9:380-385, 1991.
Rosnet et al., “MurineFlt3, a gene encoding a novel tyrosine
Beckmann M. Patricia
Lyman Stewart D.
Gambel Phillip
Immunex Corporation
Kit Gordon
Klaniecki James E.
LandOfFree
Methods of using flt3-ligand in hematopoietic cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using flt3-ligand in hematopoietic cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using flt3-ligand in hematopoietic cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3841434